岐阜薬科大学卒業

岐阜薬科大学大学院薬学研究科博士前期課程修了

マルコ製薬株式会社・創薬研究所研究員を経て、名古屋大学大学院医学系研究科に入学

名古屋大学大学院医学系研究科修了

1. Takei Y, Kurobe M, Uchida A, Hayashi K. Serum concentration of basic fibroblast growth factor in breast cancer. Clin Chem, 40:1980-1981 (1994). Imact factor 7.1

2. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito A, Miyazaki S, Maeda K, Tatemichi N, Takei Y. Modification of 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int, 49:861-867 (1996). Imact factor 14.8

3. Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N, Takei Y, Kondo T. Amyloid 2-microglobulin is modified with N-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int, 50:1303-1309 (1996). Imact factor 14.8

4. Takei Y, Higashira H, Yamamoto T, Hayashi K. Mitogenic activity toward human breast cancer cell line MCF-7 of two bFGFs purified from sera of breast cancer patients: co-operative role of cathepsin D. Br Cancer Res Tr 43:53-63 (1997).

5. Niwa T, Katsuzaki T, Ishizaki Y, Hayase F, Miyazaki T, Uematsu T, Tatemichi N, Takei Y. Imidazolone, a novel advanced glycation end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes. FEBS Lett, 407:297-302 (1997).

6. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest, 99:1272-1280 (1997). Imact factor 13.3

7. Niwa T, Katsuzaki T, Miyazaki S, Momoi T, Akiba T, Miyazaki T, Nokura K, Hayase F, Tatemichi N, Takei Y. Amyloid 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int, 51:187-194 (1997). Imact factor 14.8

8. Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S, Muramatsu T. Antisense oligodeoxynucleotide targeted to midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res, 61:8486-8491 (2001). Imact factor 12.5

9. Takei Y, Kadomatsu K, Itoh H, Sato W, Nakazawa K, Kubota S, Muramatsu T. 5’-, 3’-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine: its design and application for cancer therapy. J Biol Chem, 277:23800-23806 (2002).

10. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. , corresponding author.
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res, 64:3365-3370 (2004). Imact factor 12.5

11. Takei Y, Kadomatsu K, Yuasa K, Sato W, Muramatsu T. , corresponding author.
Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int J Cancer, 114:490-497 (2005).

12. Sato W, Takei Y, Yuzawa Y, Matsuo S, Kadomatsu K, Muramatsu T. Midkine antisense oligodeoxynucleotide inhibits renal damage induced by ischemic reperfusion. Kidney Int, 67:1330-1339 (2005). Imact factor 14.8

13. Takei Y, Kadomatsu K, Goto T, Muramatsu T. , corresponding author. Combinational antitumor effect of siRNA as to midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer, 107:864-873 (2006).

14. Takei Y, Nemoto T, Mu P, Fujishima F, Ishimoto T, Hayakawa Y, Yuzawa Y, Matsuo S, Muramatsu T, Kadomatsu K. , corresponding author. In vivo silencing of a molecular target by short interfering RNA electroporation: Tumor vascularization correlates to delivery efficiency. Mol Cancer Ther, 7:211-221 (2008).

15. Ishimoto T, Takei Y, Yuzawa Y, Hanai K, Nagahara S, Tarumi Y, Matsuo S, Kadomatsu K. , corresponding author. Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. Mol Ther, 16:387-95 (2008). Imact factor 12.1

16. Sakamoto I, Ito Y, Mizuno M, Suzuki Y, Sawai A, Tanaka A, Maruyama S, Takei Y, Yuzawa Y, Matsuo S. Lymphatic vessels develop in tubulo-interstitial fibrosis. Kidney Int, 75:828-838 (2009). Imact factor 14.8

17. Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu, K, Takei Y. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: Combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer, 125:2978-2990 (2009).

18. Nagano A, Ohno T, Shimizu K, Hara A, Yamamoto T, Kawai G, Saitou M, Takigami I, Matsuhashi A, Yamada K, Takei Y. EWS/Fli-1 chimeric fusion gene up-regulates vascular endothelial growth factor-A. Int J Cancer, 126:2790-2798 (2010).

19. Takei Y, Takigahira M, Mihara K, Tarumi Y, Yanagihara K. , corresponding author.
The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res, 71:1442-1453 (2011). Imact factor 12.5

20. Mihara K, Bhattacharyya J, Kitanaka A, Yanagihara K, Kubo T, Takei Y, Asaoku H, Takihara Y, Kimura A. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia, 26:365-367 (2012).

21. Inaba S, Nagahara S, Makita N, Tarumi Y, Ishimoto T, Matsuo S, Kadomatsu K, Takei Y. Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther, 20:356-366 (2012). Imact factor 12.1

22. Suzuki Y, Ito Y, Mizuno M, Kinashi H, Sawai A, Noda Y, Mizuno T, Shimizu H, Fujita Y, Matsui K, Maruyama S, Imai E, Matsuo S, Takei Y. Transforming growth factor-β induces vascular endothelial growth factor-C expression leading to lymphangiogenesis in rat unilateral ureteral obstruction. Kidney Int, 81:865-879 (2012). Imact factor 14.8

23. Kinashi H, Ito Y, Mizuno M, Suzuki Y, Terabayashi T, Nagura F, Hattori R, Matsukawa Y, Mizuno T, Noda Y, Nishimura H, Nishio R, Maruyama S, Imai E, Matsuo S, Takei Y. TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis. J Am Soc Nephrol, 24:1627-1642 (2013).

24. Takei Y. Electroporation-mediated siRNA delivery into tumors. Methods Mol Biol, 1121: 131-138 (2014).

25. Takei Y, Ohnishi N, Kisaka M, Mihara K. , corresponding author. Determination of abnormally expressed microRNAs in bone marrow smears from patients with follicular lymphomas. SpringerPlus, 3: 288 (2014).

26. Yuan Y, Makita N, Cao D, Mihara K, Kadomatsu K, Takei Y. Atelocollagen-mediated intravenous siRNA delivery specific to tumor tissues orthotopically xenografted in prostates of nude mice, and its anticancer effects.
Nucleic Acid Ther, 25: 85-94 (2015).

27. Terabayashi T, Ito Y, Mizuno M, Suzuki Y, Kinashi H, Sakata F, Tomita T, Iguchi D, Tawada M, Nishio R, Maruyama S, Imai E, Matsuo S, Takei Y. Vascular endothelial growth factor receptor-3 is a novel target to improve net ultrafiltration in methylglyoxal-induced peritoneal injury. Lab Invest, 95: 1029-1043 (2015).

28. Tawada M, Ito Y, Hamada C, Honda K, Mizuno M, Suzuki Y, Sakata F, Terabayashi T, Matsukawa Y, Maruyama S, Imai E, Matsuo S, Takei Y. Vascular endothelial cell injury is an important factor in the development of encapsulating peritoneal sclerosis in long-term peritoneal dialysis patients. PLoS One, 11: e0154644 (2016).

29. Sakata F, Ito Y, Mizuno M, Sawai A, Suzuki Y, Tomita T, Tawada M, Tanaka A, Hirayama A, Sagara A, Wada T, Maruyama S, Soga T, Matsuo S, Imai E, Takei Y. Sodium chloride promotes tissue inflammation via osmotic stimuli in sub-total-nephrectomized mice. Lab Invest, 97: 432-446 (2017).

30. Takei Y, Shen G, Morita-Kondo A, Hara T, Mihara K, Yanagihara K.
, corresponding author. MicroRNAs regulating epithelial-mesenchymal transition can